Abstract��
OBJECTIVE To review the latest research progress in HIV-1 integrase inhibitors. METHODS The research progress of the three marketed integrase inhibitor drugs and the integrase inhibitors with new mechanism were summarized according to the related articles. RESULTS AND CONCLUSION HIV-1 integrase as a novel target of new anti-AIDS drugs is one of the most essential enzymes for viral replication cycle. With the drug resistance of HIV becoming serious, integrase inhibitors as the new anti-AIDS drugs which have new mechanism of action can provide more choices to clinic. The research and development of integrase inhibitors with novel target and multiple targets have better prospect in the treatment of HIV.
MA Shuai,
GAO Wen-Lei,
ZHAO Jun etc
.Research Progress in HIV-1 Integrase Inhibitors[J] Chinese Pharmaceutical Journal, 2014,V49(21): 1877-1881
��
[1]
WHO. HIV/AIDS[EB/OL]. (2013-10-30)[2014-4-15]. http://www.who.int/mediacentre/factsheets/fs360/en/.[2] WHO. HIV/AIDS[EB/OL]. (2013-10-30)[2014-4-15]. http://www.who.int/features/qa/71/en/.[3] POMMIER Y, JOHNSON A A, MARCHAND C. Integrase inhibitors to treat HIV/AIDS[J]. Nat Rev Drug Discov, 2005, 4(3): 236-248.[4] WILKINSON T A, JANUSZYK K, PHILLIPS M L, et al. Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase[J]. J Biol Chem, 2009, 284(12): 7931-7939.[5] DOBARD C W, BRIONES M S, CHOW S A. Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription[J]. J Virol, 2007, 81(18): 10037-10046.[6] LU R, GHORY H Z, ENGELMAN A. Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase[J]. J Virol, 2005, 79(16): 10356-10368.[7] HAZUDA D J, YOUNG S D, GUARE J P, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques[J]. Science, 2004, 305(5683): 528-532.[8] HARE S, GUPTA S S, VALKOV E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer[J]. Nature, 2010, 464(7286): 232-236.[9] COCOHOBA J, DONG B J. Raltegravir: The first HIV integrase inhibitor[J]. Clin Ther, 2008, 30(10): 1747-1765.[10] FDA expands use of HIV drug Isentress to children and adolescents [EB/OL]. (2011-12-21)[2014-4-28]. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm284473.htm.[11] IWAMOTO M, WENNING L A, PETRY A S, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects[J]. Clin Pharmacol Ther, 2008, 83(2): 293-299.[12] RIZK M L, HANG Y, LUO W L, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-na ve HIV-infected patients[J]. Antimicrob Agents Chemother, 2012, 56(6): 3101-3106.[13] BRAINARD D M, FRIEDMAN E J, JIN B, et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics[J]. J Clin Pharmacol, 2011, 51(3): 422-427.[14] HICKS C, GULICK R M. Raltegravir: The first HIV type 1 integrase inhibitor[J]. Clin Infect Dis, 2009, 48(7): 931-939.[15] LIEDTKE M D, TOMLIN C R, LOCKHART S M, et al. Long-term efficacy and safety of raltegravir in the management of HIV infection[J]. Infect Drug Resist, 2014, 7: 73-84.[16] Approval of new fixed dose combination, Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) [EB/OL]. (2012-08-27)[2014-4-29]. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ucm317204.htm.[17] European Commission Approves Gilead��s Vitekta, an Integrase Inhibitor for the Treatment of HIV-1 Infection[EB/OL]. (2013-11-18) [2014-4-29]. http://www.gilead.com/news/press-releases/2013/11/european-commission-approves-gileads-vitekta-an-integrase-inhibitor-for-the-treatment-of-hiv1-infection.[18] Gilead Sciences�� New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA[EB/OL]. (2014-04-21) [2014-4-29]. http://www.gilead.com/news/press-releases/2014/4/gilead-sciences-new-drug-applications-for-cobicistat-and-elvitegravir-for-hiv-therapy-accepted-by-us-fda.[19] RAMANATHAN S, MATHIAS A A, GERMAN P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir[J]. Clin Pharmacokinet, 2011, 50(4): 229-244.[20] MATHIAS A A, WEST S, HUI J, et al. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure[J]. Clin Pharmacol Ther, 2009, 85(1): 64-70.[21] METIFIOT M, VANDEGRAAFF N, MADDALI K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143[J]. AIDS, 2011, 25(9):1175-1178.[22] ELION R, MOLINA J M, RAMON ARRIBAS LOPEZ J, et al. A randomized phase 3 study comparing once-daily elvitegravir with twicedaily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results[J]. J Acquir Immune Defic Syndr, 2013, 63(4): 494-497.[23] DEEKS. Elvitegravir: A review of its use in adults with HIV-1 infection[J]. Drugs, 2014, 74(6): 687-697.[24] FDA approves new drug to treat HIV infection[EB/OL]. (2013-08-12) [2014-4-29]. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm364744.htm.[25] BALLANTYNE A D, PERRY C M. Dolutegravir: First global approval[J]. Drugs, 2013, 73(14): 1627-1637.[26] REESE M J, SAVINA P M, GENERAUX G T, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor[J]. Drug Metab Dispos, 2013, 41(2): 353-361.[27] CASTELLINO S, MOSS L, WAGNER D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans[J]. Antimicrob Agents Chemother, 2013, 57(8): 3536-3546.[28] SONG I, BORLAND J, CHEN S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir[J]. Antimicrob Agents Chemother, 2012, 56(3): 1627-1629.[29] WELLER S, BORLAND J, CHEN S, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment[J]. Eur J Clin Pharmacol, 2014, 70(1): 29-35.[30] WAINBERG M A, MESPLEDE T, QUASHIE P K. The development of novel HIV integrase inhibitors and the problem of drug resistance[J]. Curr Opin Virol, 2012, 2(5): 656-662.[31] RAFFI F, RACHLIS A, STELLBRINK H J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study[J]. Lancet, 2013, 381(9868): 735-743.[32] CLOTET B, FEINBERG J, VAN LUNZEN J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study[J]. Lancet, 2014, 383(9936): 2222-2231.[33] New HIV drug to become leading treatment by 2016[EB/OL]. (2014-01-29) [2014-05-02] http://www. datamonitorhealthcare. com/new-hiv-drug-to-become-leading-treatment-by-2016/.[34] KAWASUJI T, JOHNS B A, YOSHIDA H, et al. Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles[J]. J Med Chem, 2013, 56(3): 1124-1135.[35] SPREEN W, MIN S, FORD S L, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK125744, an HIV integrase strand transfer inhibitor[J]. HIV Clin Trials, 2013, 14(5): 192-203.[36] MIN S, DEJESUS E, MCCURDY L, et al. Pharmacokinetics (PK) and safety in healthy and HIV-infected subjects and short-term antiviral efficacy of S/GSK1265744, a next generation once daily HIV integrase inhibitor[C]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, 2009.[37] KARMON S L, MARKOWITZ M. Next-generation integrase inhibitors: Where to after raltegravir[J]. Drugs, 2013, 73(3): 213-228.[38] CHRIST F, DEBYSER Z. The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy[J]. Virology, 2013, 435(1): 102-109.[39] DESIMMIE B A, SCHRIJVERS R, DEMEULEMEESTER J, et al. LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions[J]. Retrovirology, 2013, 10: 57.[40] FENWICK C, AMAD M, BAILEY M D, et al. Preclinical profile of BI 224436, a novel HIV-1 non-catalytic site integrase inhibitor[J]. Antimicrob Agents Chemother, 2014, 58(6): 3233-3244.[41] DI SANTO R. Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain[J]. Curr Med Chem, 2011, 18(22): 3335-3342.[42] ESPOSITO F, TRAMONTANO E. Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: Single and dual active site inhibitors[J]. Antivir Chem Chemother, 2014, 23(4): 129-144.[43] COSTI R, METIFIOT M, CHUNG S, et al. Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase[J]. J Med Chem, 2014, 57(8): 3223-3234.
2014, Vol. 49 
